In the phase 3 eXalt3 study, ensartinib showed superior efficacy to crizotinib in both systemic and intracranial disease, raising the possibility of a new first-line option for patients with ALK-positive NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.